Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy

J Thorac Oncol. 2022 Feb;17(2):182-185. doi: 10.1016/j.jtho.2021.11.010.

Authors

Misako Nagasaka¹, Sai-Hong Ignatius Ou²

Affiliations

¹ University of California Irvine School of Medicine, Orange, California; Division of Neurology, Department of Internal Medicine, St. Marianna University, Kawasaki, Kanagawa, Japan.
² University of California Irvine School of Medicine, Orange, California. Electronic address: siou@hs.uci.edu.

PMID: 35074224
DOI: 10.1016/j.jtho.2021.11.010

No abstract available

Publication types

Editorial
Comment

MeSH terms

Alternative Splicing
Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Muscular Atrophy, Spinal*
Oncogene Proteins, Fusion / genetics
Oncogene Proteins, Fusion / metabolism

Substances

EML4-ALK fusion protein, human
Oncogene Proteins, Fusion
Anaplastic Lymphoma Kinase